Opdivo (nivolumab) Global Market Report 2025

Global Opdivo (nivolumab) Market Report 2025

Opdivo (nivolumab) Global Market Report 2025 ) – By Type (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL), By Dosage (Injection, Solution, Other Dosages), By Demographic (Adult, Pediatric), By Application (Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications), By End-User (Hospitals, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Opdivo (nivolumab) Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Opdivo (nivolumab) Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Opdivo (nivolumab) Global Market Report 2025

Proud Members Of

Opdivo (nivolumab) Market Definition

Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the body's immune system to detect and destroy cancer cells.

The main types in the opdivo (nivolumab) market are 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ML dosage of Opdivo is a lower concentration of the drug, designed to be administered to patients requiring a smaller dose, commonly used for specific treatment protocols or lower-weight patients. The various dosages include injection, solution, and others, and several demographics including adult and pediatric. The different applications include Melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and others. The end-users encompass hospitals, clinics, and others.

Opdivo (nivolumab) Market Segmentation

The opdivo (nivolumab)market covered in this report is segmented –

1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL

2) By Dosage: Injection, Solution, Other Dosages

3) By Demographic: Adult, Pediatric

4) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

5) By End-User: Hospitals, Clinics, Other End Users

Opdivo (nivolumab) Market Size and growth rate 2025 to 2029: Graph

Opdivo (nivolumab) Market Size 2025 And Growth Rate

The opdivo (nivolumab) market size has grown strongly in recent years. It will grow from $7,709.49 million in 2024 to $8,335.54 million in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising prevalence of cancer, rising expenditure for research and development proficiencies, growing investment in healthcare facilities, increasing incidence of non-small lung cancer, and growth in healthcare expenditure for capital equipment.

Opdivo (nivolumab) Market Growth Forecast

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $11,281.56 million in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing acceptance of immunotherapy, enhanced understanding of immunotherapy and its benefits, growth in healthcare expenditure for capital equipment, increasing the application of nivolumab for various indications, and growing preference for immunotherapy treatments. Major trends in the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, growing trend towards personalized medicine, and advancements in cancer research.

Book your 30 minutes free consultation with our research experts

Opdivo (nivolumab) Market Driver: Impact of Rising Non-Small Cell Lung Cancer Incidence on Opdivo (Nivolumab) Market Growth

Increasing incidence of non-small lung cancer is expected to propel the growth of the opdivo (nivolumab) market going forward. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. The increasing incidence of non-small cell lung cancer (NSCLC) is primarily attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, thereby enhancing the body's immune response to recognize and attack cancer cells. For example, in 2024, the American Cancer Society, a US-based health organization, reported that 234,580 new cases of lung cancer were diagnosed in the US, with 80% of those being non-small cell lung cancer (NSCLC), marking an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Thus, increasing incidence of non-small lung cancer is driving the growth of the opdivo (nivolumab) market.

Global Opdivo (nivolumab) Market Major Players

Major companies operating in the opdivo (nivolumab) market include Bristol-Myers Squibb, Ono Pharmaceutical

Global Opdivo (nivolumab) Market Trend: Opdivo (Nivolumab) Market Growth Driven by FDA Approvals for Combination Therapies in NSCLC

The key trend in the opdivo (nivolumab) market is developing combination therapies to enhance the efficacy of treatment, expand its applications across multiple cancer types. Combination approaches aim to overcome resistance mechanisms and provide more comprehensive treatment options for advanced cancer patients. For instance, in October 2024, Food and Drug Administration, a US-based federal agency, approved Opdivo (nivolumab) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable non-small cell lung cancer. This approval allows Opdivo to be used in combination with platinum-doublet chemotherapy before surgery and as a monotherapy after surgery for patients who do not have known EGFR or ALK mutations.

Opdivo (nivolumab) Market Merger And Acquisition: Lyvgen Biopharma Partners With Bristol Myers Squibb For Phase II Clinical Trial Of LVGN7409 And Opdivo In NSCLC

In November 2022, Lyvgen Biopharma, a China-based biotech company, partnered with Bristol Myers Squibb (BMS). The partnership aims to conduct a Phase II clinical trial evaluating LVGN7409 in combination with Opdivo (nivolumab) for patients with advanced or metastatic non-small cell lung cancer (NSCLC). Bristol Myers Squibb is a pharmaceutical company developing Opdivo (nivolumab).

Regional Outlook For The Global Opdivo (nivolumab) Market

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the opdivo (nivolumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Opdivo (nivolumab) Market?

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Opdivo (nivolumab) Industry?

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Opdivo (nivolumab) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	CAGR of 7.9% from 2025 to 2034
Revenue Forecast In 2034	2024
Growth Rate	2019-2024
Base Year For Estimation	2025 - 2029 - 2034
Actual Estimates/Historical Data	Revenue in USD Billion and CAGR from 2025 to 2034
Forecast Period	1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL 2) By Dosage: Injection, Solution, Other Dosages 3) By Demographic: Adult, Pediatric 4) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications 5) By End-User: Hospitals, Clinics, Other End Users
Market Representation	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Segments Covered	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Regional Scope	Bristol-Myers Squibb, Ono Pharmaceutical
Country Scope	Request for Sample
Key Companies Profiled	Explore Purchase Options
Customization Scope
Pricing And Purchase Options

1. Executive Summary

2. Opdivo (Nivolumab) Market Characteristics

3. Opdivo (Nivolumab) Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Opdivo (Nivolumab) Market Trends And Strategies

5. Opdivo (Nivolumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Opdivo (Nivolumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Opdivo (Nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis

6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)

7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts

8. Opdivo (Nivolumab) Market Segmentation

8.1. Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

40 mg/4 mL

100 mg/10 mL

240 mg/24 mL

8.2. Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injection

Solution

Other Dosages

8.3. Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Adult

Pediatric

8.4. Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Melanoma

Non-small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Classical Hodgkin Lymphoma (CHL)

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Renal Cell Carcinoma (RCC)

Other Applications

8.5. Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Other End Users

9. Global Opdivo (Nivolumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Opdivo (Nivolumab) Market Regional And Country Analysis

10.1. Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Opdivo (Nivolumab) Market

11.1. Asia-Pacific Opdivo (Nivolumab) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Opdivo (Nivolumab) Market

12.1. China Opdivo (Nivolumab) Market Overview

12.2. China Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.3. China Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.4. China Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Opdivo (Nivolumab) Market

13.1. India Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. India Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. India Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Opdivo (Nivolumab) Market

14.1. Japan Opdivo (Nivolumab) Market Overview

14.2. Japan Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. Japan Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. Japan Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Opdivo (Nivolumab) Market

15.1. Australia Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.2. Australia Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Australia Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Opdivo (Nivolumab) Market

16.1. South Korea Opdivo (Nivolumab) Market Overview

16.2. South Korea Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. South Korea Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.4. South Korea Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Opdivo (Nivolumab) Market

17.1. Western Europe Opdivo (Nivolumab) Market Overview

17.2. Western Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Western Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.4. Western Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Opdivo (Nivolumab) Market

18.1. UK Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. UK Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. UK Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Opdivo (Nivolumab) Market

19.1. Germany Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Germany Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Germany Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Opdivo (Nivolumab) Market

20.1. France Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. France Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. France Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Opdivo (Nivolumab) Market

21.1. Eastern Europe Opdivo (Nivolumab) Market Overview

21.2. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Opdivo (Nivolumab) Market

22.1. North America Opdivo (Nivolumab) Market Overview

22.2. North America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. North America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.4. North America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Opdivo (Nivolumab) Market

23.1. USA Opdivo (Nivolumab) Market Overview

23.2. USA Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. USA Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. USA Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Opdivo (Nivolumab) Market

24.1. Canada Opdivo (Nivolumab) Market Overview

24.2. Canada Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. Canada Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. Canada Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Opdivo (Nivolumab) Market

25.1. South America Opdivo (Nivolumab) Market Overview

25.2. South America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. South America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. South America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Opdivo (Nivolumab) Market

26.1. Middle East Opdivo (Nivolumab) Market Overview

26.2. Middle East Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. Middle East Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. Middle East Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Opdivo (Nivolumab) Market

27.1. Africa Opdivo (Nivolumab) Market Overview

27.2. Africa Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Africa Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.4. Africa Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Opdivo (Nivolumab) Market Competitive Landscape And Company Profiles

28.1. Opdivo (Nivolumab) Market Competitive Landscape

28.2. Opdivo (Nivolumab) Market Company Profiles

28.2.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

28.2.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

29. Global Opdivo (Nivolumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Opdivo (Nivolumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Opdivo (Nivolumab) Market

32. Recent Developments In The Opdivo (Nivolumab) Market

33. Opdivo (Nivolumab) Market High Potential Countries, Segments and Strategies

33.1 Opdivo (Nivolumab) Market In 2029 - Countries Offering Most New Opportunities

33.2 Opdivo (Nivolumab) Market In 2029 - Segments Offering Most New Opportunities

33.3 Opdivo (Nivolumab) Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: South Korea, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: South Korea, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: South Korea, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: UK, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: UK, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: UK, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Germany, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Germany, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Germany, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: France, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: France, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: France, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: North America, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: North America, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: North America, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: USA, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: USA, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: USA, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Canada, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Canada, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Canada, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: South America, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: South America, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: South America, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Middle East, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Middle East, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Middle East, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Africa, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Africa, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: Africa, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Bristol-Myers Squibb Financial Performance

Table 62: Ono Pharmaceutical Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: South Korea, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: South Korea, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: South Korea, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Western Europe, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: UK, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: UK, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: UK, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Germany, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Germany, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Germany, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: France, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: France, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: France, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Eastern Europe, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: North America, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: North America, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: North America, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: USA, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: USA, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: USA, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Canada, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Canada, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Canada, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: South America, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: South America, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: South America, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Middle East, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Middle East, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Middle East, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Africa, Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Africa, Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: Africa, Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Bristol-Myers Squibb Financial Performance

Figure 62: Ono Pharmaceutical Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the anti-parkinson drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth

Protein Assays Global Market Report 2025 – By Product Type (Reagents And Kits, Instruments), By Technology Type (Absorbance Based Protein Assays, Colorimetric Protein Assays, Fluorescence Based Protein Assays), By End User (Pharmaceutical Industry, Biotechnology Industry, Clinical Laboratories, Hospitals, Academic Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Therapeutic Proteins Global Market Report 2025 – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics), By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Protein Sequencing Global Market Report 2025 – By Product And Service (Protein Sequencing Products, Protein Sequencing Services), By Application (Bio-Therapeutics, Genetic Engineering, Other Applications), By End User 3 (Pharmaceutical And Biotechnology Companies, Other End-Users ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Protein Extracts From Single Cell Protein And Other Conventional Sources Global Market Report 2025 – By Source (Plant Protein Extract Sources, Microbial Sources - Single Cell Proteins, Microbial Sources - Direct Use), By Feedstock (Organic, Conventional), By Application (Biotechnology, Animal Feed, Agriculture And Fertilizers, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Research-Grade Proteins Global Market Report 2025 – By Product (Cytokines And Growth Factors, Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products), By Host Cell (Mammalian Cells, Bacterial Cells, Fungi And Yeast, Insect Cells, Other Host Cells), By End-Use (Pharmaceutical And Biotechnology Companies, Academic And Research Institute, Other End-Uses) – Market Size, Trends, And Global Forecast 2025-2034

View Report

PEGylated Proteins Global Market Report 2025 – By Product (Consumable And Services, PEGylation Kits And Reagents, Monofunctional Linear PEGs, Bifunctional PEGs, Services, Other Products), By Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VII, Other Protein Types), By Application (Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Other Applications), By End User (Pharmaceuticals, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Protein Chip Global Market Report 2025 – By Product (Lab-On-Chip, Integrated System, Arrays, Microarrays System), By Technology (Analytical Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays), By Application (Diagnostics, Proteomics, Antibody Characterization), By End User (Hospitals And Clinics, Academic And Research Institutes, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cell Culture Protein Surface Coating Global Market Report 2025 – By Coating Type (Pre-Coating, Multiwall Or Microwell Plates, Flasks, Petri Dishes, Slides, Cover Slips, Self-Coating), By Protein Source (Animal-Derived Protein, Human-Derived Protein, Synthetic Protein, Plant-Derived Protein), By Application (Scientific Research, Industrial Production) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Opdivo (nivolumab) market?

How will the Opdivo (nivolumab) market drivers and restraints affect the market dynamics? What forces will shape the Opdivo (nivolumab) industry going forward?

The Opdivo (nivolumab) market major growth driver - Impact of Rising Non-Small Cell Lung Cancer Incidence on Opdivo (Nivolumab) Market Growth. For further insights on the Opdivo (nivolumab) market, request a sample here

What is the forecast market size or the forecast market value of the Opdivo (nivolumab) market?

The Opdivo (nivolumab) market size has grown strongly in recent years. The opdivo (nivolumab) market size has grown strongly in recent years. It will grow from $7,709.49 million in 2024 to $8,335.54 million in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising prevalence of cancer, rising expenditure for research and development proficiencies, growing investment in healthcare facilities, increasing incidence of non-small lung cancer, and growth in healthcare expenditure for capital equipment. The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $11,281.56 million in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing acceptance of immunotherapy, enhanced understanding of immunotherapy and its benefits, growth in healthcare expenditure for capital equipment, increasing the application of nivolumab for various indications, and growing preference for immunotherapy treatments. Major trends in the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, growing trend towards personalized medicine, and advancements in cancer research. For further insights on the Opdivo (nivolumab) market, request a sample here

How is the Opdivo (nivolumab) market segmented?

The opdivo (nivolumab)market covered in this report is segmented –
1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users For further insights on the Opdivo (nivolumab) market, request a sample here

Which region has the largest share of the Opdivo (nivolumab) market? What are the other regions covered in the report?

Who are the major players in the Opdivo (nivolumab) market?

Major companies operating in the opdivo (nivolumab) market include Bristol-Myers Squibb, Ono Pharmaceutical . For further insights on the Opdivo (nivolumab) market, request a sample here.

What are the key trends in the Opdivo (nivolumab) market?

Major trends in the Opdivo (nivolumab) market include Opdivo (Nivolumab) Market Growth Driven by FDA Approvals for Combination Therapies in NSCLC. For further insights on the Opdivo (nivolumab) market, request a sample here.

What are the major opportunities in the Opdivo (nivolumab) market? What are the strategies for the Opdivo (nivolumab) market?

For detailed insights on the major opportunities and strategies in the Opdivo (nivolumab) market, request a sample here.

How does the Opdivo (nivolumab) market relate to the overall economy and other similar markets?

For detailed insights on Opdivo (nivolumab)'s relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Opdivo (nivolumab) industry?

For detailed insights on the mergers and acquisitions in the Opdivo (nivolumab) industry, request a sample here.

What are the key dynamics influencing the Opdivo (nivolumab) market growth? SWOT analysis of the Opdivo (nivolumab) market.

For detailed insights on the key dynamics influencing the Opdivo (nivolumab) market growth and SWOT analysis of the Opdivo (nivolumab) industry, request a sample here.